ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Personalized drug dosing may boost immune recovery after stem cell transplant
Disease control OngoingThis study tests whether giving a personalized dose of rabbit ATG (a drug that helps prevent transplant rejection) before a stem cell transplant can help the immune system recover faster and reduce side effects. It includes children and adults with acute leukemia or myelodysplast…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New drug combo aims to stop blood cancer relapse after transplant
Disease control OngoingThis study is for people with high-risk blood cancers (AML, MDS, CMML) who are getting a donor stem cell transplant. Researchers want to see if adding the drug venetoclax to standard transplant preparation and to post-transplant maintenance therapy is safe and can help prevent th…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated May 26, 2026 03:07 UTC
-
New pill aims to keep leukemia in remission for chinese patients
Disease control OngoingThis study looks at how well and how safely the drug ONUREG (oral azacitidine) works in Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants take ONUREG as a maintenance therapy to help prevent the cancer from comin…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Shorter drug combo may ease treatment for older AML patients
Disease control OngoingThis study tests a shorter, 5-day course of azacitidine combined with venetoclax for adults with acute myeloid leukemia (AML) who cannot tolerate standard intensive chemotherapy. The goal is to see if the shorter regimen reduces side effects like infections and hospital stays whi…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for older AML patients with FLT3 mutation: triple therapy trial underway
Disease control OngoingThis study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with a fast-growing type of acute myeloid leukemia (AML) who cannot have standard chemotherapy. The goal is to find the best dose and see how well the treatment con…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 20, 2026 12:08 UTC
-
Lab-Made donor cells aim to beat cancer without the side effects
Disease control OngoingThis study is for children and young adults up to age 21 with high-risk blood cancers like leukemia or lymphoma. It tests a transplant using specially treated donor cells from a family member to reduce the risk of the cancer coming back while lowering the chance of a serious side…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 18, 2026 12:07 UTC